Dexamethasone Eye Drops to Prevent Treatment-Requiring Retinopathy of Prematurity
JAMA Pediatrics · 01.11.2026 · 180 (11) · 1204
DOI: 10.1001/jamapediatrics.2026.3247 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Pediatrics, erschienen am 01.11.2026. Verfasst von Ann Hellström und 18 weiteren Autor:innen. Beteiligte Einrichtung: Sahlgrenska Centre for Pediatric Ophthalmology Research, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska A…. Hauptthemen laut MEDLINE: Dexamethasone, Glucocorticoids, Retinopathy of Prematurity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Current treatment for type 1 retinopathy of prematurity (ROP), including laser photocoagulation and intravitreal anti–vascular endothelial growth factor therapy, is invasive but necessary to prevent blindness. Experimental evidence and limited clinical experience suggest that topical steroids may reduce disease progression and the need for invasive treatment.
Objective
To evaluate whether dexamethasone eye drops reduce the proportion of preterm infants with prethreshold ROP progressing to treatment-requiring type 1 ROP. Design, Setting, and Participants The DROPROP trial was a double-masked randomized clinical trial at 6 university hospitals and 8 county hospitals in Sweden. It evaluated infants born before 30 weeks’ gestational age (GA), from 2022 to 2025, with severe ROP. Data analysis was performed from November 2025 to January 2026. Exposures Infants were randomized to receive dexamethasone eye drops (1 mg/mL) or placebo (saline). One eye drop was administered every day or every other day for up to 12 weeks. Main Outcomes and Measures The primary outcome was progression to type 1 ROP requiring invasive treatment. Logistic regression adjusted for GA and site was used for the primary analysis. Intention-to-treat analysis was performed. Adverse events were monitored as safety outcomes.
Results
Among 100 infants, the mean (SD) GA at birth was 25.1 (1.4) weeks, 42 (42.0%) were female, and the mean (SD) birth weight was 712.9 (202.1) g. In the intention-to-treat population, type 1 ROP occurred in 10 of 50 infants (20.0%) in the dexamethasone group and 19 of 50 infants (38.0%) in the placebo group (adjusted odds ratio, 0.44; 95% CI, 0.17-1.12; P = .08), corresponding to a relative risk reduction of 47%. In the per-protocol population, type 1 ROP occurred in 9 of 48 infants (18.8%) in the dexamethasone group vs 19 of 49 infants (38.8%) in the placebo group (adjusted odds ratio, 0.40; 95% CI 0.15-1.05). No clinically significant differences in adverse events were observed between groups. Conclusions and Relevance Timely administration of topical dexamethasone numerically reduced the risk of prethreshold ROP progressing to treatment-requiring type 1 ROP. Although the analysis did not reach statistical significance, these findings suggest that topical dexamethasone may be a safe, noninvasive strategy to reduce the need for invasive treatment. Trial Registration euclinicaltrials.eu Identifier: 2023-505318-97-00
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sahlgrenska Centre for Pediatric Ophthalmology Research, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Department of Ophthalmology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden.
- Learning and Leadership for Health Care Professionals, Institute of Health and Care Science at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Department of Ophthalmology, Region Jönköping County, Jönköping, Sweden.
- Pediatrics, Department of Clinical Sciences, Lund, Lund University, Skåne University Hospital, Lund, Sweden.
- Ophthalmology, Department of Clinical Sciences, Lund, Lund University, Skåne University Hospital, Lund, Sweden.
Zitieren
APA
Hellström, A., Petrishka-Lozenska, M., Sjöbom, U., Wallander, J., Nilsson, A. K., Löfqvist, C., Ley, D., Gränse, L., Öhnell, H. M., Hård, A. L., Jakobsson, G., Sävman, K., Domellöf, M., Löfgren, S., Larsson, E., Smith, L. E. H., Pivodic, A., Lundgren, P., & DROPROP Collaboration Group (2026). Dexamethasone Eye Drops to Prevent Treatment-Requiring Retinopathy of Prematurity. JAMA Pediatrics, 180(11), 1204. https://doi.org/10.1001/jamapediatrics.2026.3247
Vancouver
Hellström A, Petrishka-Lozenska M, Sjöbom U, Wallander J, Nilsson AK, Löfqvist C, et al. Dexamethasone Eye Drops to Prevent Treatment-Requiring Retinopathy of Prematurity. JAMA Pediatrics. 2026;180(11):1204. doi:10.1001/jamapediatrics.2026.3247
BibTeX
@article{Hellstrm2026,
author = {Hellström, Ann and Petrishka-Lozenska, Mariya and Sjöbom, Ulrika and Wallander, Jenny and Nilsson, Anders K and Löfqvist, Chatarina and Ley, David and Gränse, Lotta and Öhnell, Hanna Maria and Hård, Anna-Lena and Jakobsson, Gunnar and Sävman, Karin and Domellöf, Magnus and Löfgren, Stefan and Larsson, Eva and Smith, Lois E H and Pivodic, Aldina and Lundgren, Pia and DROPROP Collaboration Group, DROPROP Collaboration Group},
title = {Dexamethasone Eye Drops to Prevent Treatment-Requiring Retinopathy of Prematurity},
journal = {JAMA Pediatrics},
year = {2026},
volume = {180},
number = {11},
pages = {1204},
doi = {10.1001/jamapediatrics.2026.3247}
}
EUVIMED